Qiming Venture Partners is a leading venture capital firm that invests in innovative companies across China and the US. The firm focuses on early to expansion stage investments in the TMT (Technology, Media, and Telecommunications) and Healthcare sectors. Qiming has a track record of backing disruptive and high-growth companies that aim to address large, unmet market needs.

Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), UBTech (SEHK:9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology, among many others.

COM:QIMINGVC

Qiming Venture Partners